Addressing unregulated stem cell treatment centers

In recent years hundreds of unregulated stem cell treatment centers have cropped up across the U.S. These clinics claim to offer treatments for a wide variety of diseases and ailments by using patients’ own stem cells. These centers often use high-pressure sales tactics to prey on individuals and families who are desperate for cures. All the while, the ongoing use of these questionable and unproven practices risk poisoning the public’s good will and could jeopardize legitimate research programs whose results may still be years away.

In a recent article the Washington Post details the experiences of one individual who lost her vision after one such treatment. This is a highly recommended read that also highlights the work of attorney Andrew Yaffa in pursuing these dubious centers as well as comments from our founder Sally Temple.

Read the article at the Washington Post

New FDA designation opens the door for stem cell trials

Dr. Temple contributed to a recent article on a stem cell clinical trial that has recently received the Food and Drug Administration’s new Regenerative Medicine Advanced Therapy (RMAT) designation.

Read more about how this new designation will help to promote the advancement of legitimate stem cell therapies: https://www.the-scientist.com/?articles.view/articleNo/51539/title/Trends-in-Synthetic-Biology–Antibody-Engineering/

Dr. Messer hosts webinar for “The Scientist”

Dr. Anne Messer was one of two experts chosen to present a webinar for The Scientist (March 8, 2018.) Antibodies are the fastest growing class of synthetic therapeutics, and Dr. Messer’s presentation covered their development and use as therapeutics and markers for neurodegenerative diseases. She described cutting-edge design and optimization approaches, as well as offering insight on future directions in antibody engineering. Human stem cell lines and assays at NSCI allow screening and testing for which of these engineered antibodies and their variants should be carried forward as clinical drug candidates. The session had 581 registrants and 148 live viewers who also asked questions at the end of the presentations.

https://www.the-scientist.com/?articles.view/articleNo/51539/title/Trends-in-Synthetic-Biology–Antibody-Engineering/

Support NSCI on November 28th, #GivingTuesday

nsci-banner-2016-givetues

Celebrate your kindness on #GivingTuesday.

On #GivingTuesday, a national day of donation, consider a gift to the Neural Stem Cell Institute. Your gift gets us closer to therapies for incurable diseases of the central nervous system including Macular Degeneration, Alzheimer’s, Parkinson’s, Spinal Cord Injury and Autism. Your support inspires our ongoing research and brings us closer to cures.

Your gracious contribution can be made by clicking here. Or, by mailing a check made out to Regenerative Research Foundation to: 1 Discovery Drive, Rensselaer, NY 12144.

Or, as you begin your holiday shopping simply include us through Amazon Smile. When you shop at Amazon the AmazonSmile Foundation will donate 0.5% of the purchase price from your eligible smile.amazon.com purchases.

  1. Go to https://smile.amazon.com ,
  2. log in to your amazon account
  3. Choose “Regenerative Research Foundation” in Rensselaer, it should look like this…
    screen-shot-2016-11-16-at-13-41-54
  4. Now, when ever you shop at Amazon you’ll see that you are supporting us…
    screen-shot-2016-11-16-at-14-10-35

However you choose to give, we celebrate your support. Your gift gets us closer to helping so many.  Thank you!

Unique Surgical Technique Published in Video Journal

NSCI Researchers Create Unique Surgical Technique to Aide Research in Quest for Retinal Disease Therapeutic

RENSSELAER N.Y., August 30, 2017 Age-related macular degeneration (AMD), a progressive degenerative disease of the retina, is the leading cause of blindness in the elderly. Patients with AMD gradually lose central vision, severely compromising the ability of a person to perform everyday tasks, including reading. AMD affects more than 10 million people in the US and is projected to increase to 196 million in 2020 worldwide. Scientists at the Neural Stem Cell Institute, including former NSCI researcher Christine Zhao and NSCI Principal Investigator Dr. Nathan Boles, have now published a breakthrough technique in the video journal Jove.

In AMD, the retinal pigment epithelium (RPE), a pigmented layer of cells lying beneath and supporting the retina, degenerates. AMD occurs in two forms, dry and wet. While there are therapies for the wet form of AMD, there are no approved therapies for the dry form of AMD. The advent of induced pluripotent stem cell (iPSCs), and their ability to generate any cell type in the body, has enabled the creation of cell culture models of disease that enable rapid drug screening for potential therapeutic agents.

Zhao and her team created a unique surgical technique to deliver cells to the sub-retical space of rat eyes: Subretinal injection has been widely applied in preclinical studies of stem cell replacement therapy for age-related macular degeneration. In this visualized article, we describe a less risky, reproducible and precisely modified subretinal injection technique via the trans-scleral approach to deliver cells into rat eyes.

View complete video journal here.

Former NSCI Researcher Dr. Christine Zhao

NSCI Principal Investigator Dr.Nathan Boles